LAPIX Therapeutics, Inc., a biopharmaceutical company dedicated to the development of innovative orally deliverable therapies for autoimmune diseases, has initiated the Phase 1 clinical trial for its LPX-TI641 therapy

BostonGene, a leading provider of AI-driven solutions for molecular and immune profiling, has announced a collaboration with LegoChem Biosciences, Inc. (LCB), a clinical-stage biopharmaceutical company specializing in the development

Acorda Therapeutics, Inc, has made an announcement regarding new regulatory submissions for the approval of INBRIJA® (levodopa inhalation powder) in six Latin American countries through its partner,

Halozyme Therapeutics, Inc, has recently announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals. This partnership grants Acumen access to Halozyme's ENHANZE® drug delivery technology,

BioCina Pty Ltd., a globally renowned biologics contract development and manufacturing organization, has recently announced an expanded partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company focused on developing Gamma-PN™

Immutep Limited has released new biomarker data from its Phase II trial, in which they investigated eftilagimod alpha, a soluble LAG-3 protein and first-in-class MHC Class II agonist administered subcutaneously. This trial examined efti in conjunction

Regulus Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery and development of innovative medicines targeting microRNAs. The company, also known as Regulus,

Bayer and the Broad Institute of MIT and Harvard recently announced the extension of their research partnership for another five years, following a decade of successful collaboration. This renewed agreement

Kyverna Therapeutics, a clinical-stage company specializing in cell therapy and focused on developing innovative treatments for severe autoimmune diseases, has recently entered into a multi-year research funding agreement

Prelude Therapeutics Incorporated and AbCellera have recently unveiled a multi-year, multi-program partnership aimed at the exploration, advancement, and market launch of innovative treatments for cancer patients.